Oxford, UK, 03 June 2020: Epigenetics company Base Genomics has launched with a team of leading scientists and clinicians to set a new gold standard in DNA methylation detection. The company has closed an oversubscribed seed funding round of $11 million USD (£9 million GBP) to progress development of its TAPS technology, initially focusing on developing a blood test for early-stage cancer and minimal residual disease. The funding round was led by Oxford Sciences Innovation and also included investors with industry expertise in genomics and oncology.
Base Genomics raise $11M
Epigenetics company Base Genomics has launched with a team of leading scientists and clinicians to set a new gold standard in DNA methylation detection.
